Could less be more? new trial tests lower drug dose to tame myeloma side effects
NCT ID NCT07181941
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether people with multiple myeloma that has come back or stopped responding to other treatments can safely take a lower dose of the drug linvoseltamab once their cancer starts to improve. Linvoseltamab works by helping the body's immune cells find and kill myeloma cells. The goal is to see if reducing the dose can lower side effects while still keeping the cancer under control. About 30 adults will take part in this early-phase trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Linvoseltamab (a bispecific antibody that helps immune cells attack cancer cells)
What this could lead to
If successful, this could show that lowering the dose of linvoseltamab after an early response reduces side effects without losing control of the cancer.
What could go wrong
This is an early-phase trial with only 30 participants, so results may not apply to all patients. Lowering the dose could also lead to the cancer returning sooner.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact